Novavax, Inc., together with its subsidiary, Novavax AB, a clinical-stage biotechnology company, focuses on the discovery, development, and commercialization of recombinant nanoparticle vaccines and adjuvants. Its lead adjuvant is Matrix-M that is used to enable a vaccine to enhance the amplitude of the immune response and qualitatively change it, enhance its specificity to provide protection against related microorganisms, as well as allows immunization with much lower doses of antigen. The company develops respiratory syncytial (RSV) virus fusion protein nanoparticle vaccine candidate for infants via maternal immunization in Phase III clinical trial; older adults in Phase II clinical trial; and children six months to five years of age in Phase I clinical trial. Novavax, Inc. also develops NanoFlu vaccine, which is in Phase I/II clinical trial for treating seasonal influenza in older adults; and Ebola virus glycoprotein vaccine that is in Phase I clinical trial. Its preclinical programs include Zika virus; combination respiratory vaccine candidate to protect against RSV and seasonal influenza, as well as other infectious disease vaccine candidates. Novavax, Inc. was founded in 1987 and is headquartered in Gaithersburg, Maryland.
Industry, Sector and Symbol
Industry Biological products, except diagnostic
Sub-IndustryBiotechnology
SectorMedical
Phone240-268-2000
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$31.18 million
Profitability
Miscellaneous
Employees347
Next Earnings Date3/13/2019 (Estimated)
OptionableOptionable
Novavax (NASDAQ:NVAX) Frequently Asked Questions
What is Novavax's stock symbol?
Novavax trades on the NASDAQ under the ticker symbol "NVAX."
How were Novavax's earnings last quarter?
Novavax, Inc. (NASDAQ:NVAX) announced its earnings results on Wednesday, August, 8th. The biopharmaceutical company reported ($0.12) EPS for the quarter, hitting the consensus estimate of ($0.12). The biopharmaceutical company had revenue of $10.80 million for the quarter, compared to the consensus estimate of $10.02 million. The business's quarterly revenue was up 61.2% on a year-over-year basis. During the same period in the previous year, the firm posted ($0.16) EPS. View Novavax's Earnings History.
When is Novavax's next earnings date?
What price target have analysts set for NVAX?
11 brokers have issued 1-year price targets for Novavax's stock. Their predictions range from $2.00 to $10.00. On average, they expect Novavax's stock price to reach $4.6389 in the next year. This suggests a possible upside of 141.6% from the stock's current price. View Analyst Price Targets for Novavax.
What is the consensus analysts' recommendation for Novavax?
11 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Novavax in the last year. There are currently 2 hold ratings and 9 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Novavax.
What are Wall Street analysts saying about Novavax stock?
Here are some recent quotes from research analysts about Novavax stock:
- 1. According to Zacks Investment Research, "NOVAVAX INC is a specialty biopharmaceutical company engaged in the research, development and commercialization of proprietary products focused on women's health and infectious diseases. Their technology platforms involve the use of proprietary, microscopic, organized, non-phospholipid structures as vehicles for the delivery of a wide variety of drugs and other therapeutic products, including certain hormones, anti-bacterial and anti-viral products and vaccine adjuvants. " (2/1/2019)
- 2. Cantor Fitzgerald analysts commented, ": We reaffirm our Neutral rating and $2 PT on NVAX. We believe the company’s portfolio of vaccine candidates has the potential to meaningfully improve the prevention of important infectious diseases. We think the forthcoming release of top-line data from the ResVax Phase 3 trial may be an important catalyst for the stock with the potential to de-risk the company’s most- advanced asset. In our view, understanding the need for and access to additional capital to develop pipeline assets while retaining their potential value is key to evaluating the fair value of the stock." (1/29/2019)
Has Novavax been receiving favorable news coverage?
News headlines about NVAX stock have trended negative recently, InfoTrie Sentiment Analysis reports. The research group identifies positive and negative press coverage by monitoring more than six thousand news and blog sources in real time. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores closest to five being the most favorable. Novavax earned a media sentiment score of -2.1 on InfoTrie's scale. They also gave news stories about the biopharmaceutical company a news buzz of 1.0 out of 10, meaning that recent press coverage is extremely unlikely to have an impact on the company's share price in the next few days.
Are investors shorting Novavax?
Novavax saw a increase in short interest in January. As of January 31st, there was short interest totalling 63,771,259 shares, an increase of 4.1% from the January 15th total of 61,262,737 shares. Based on an average daily trading volume, of 8,256,953 shares, the short-interest ratio is currently 7.7 days. Approximately 16.9% of the shares of the company are sold short. View Novavax's Current Options Chain.
Who are some of Novavax's key competitors?
Some companies that are related to Novavax include China Biologic Products (CBPO), Repligen (RGEN), Halozyme Therapeutics (HALO), Denali Therapeutics (DNLI), Acceleron Pharma (XLRN), Spark Therapeutics (ONCE), Aerie Pharmaceuticals (AERI), Atara Biotherapeutics (ATRA), Regenxbio (RGNX), Crispr Therapeutics (CRSP), Alector (ALEC), Momenta Pharmaceuticals (MNTA), Orchard Therapeutics (ORTX), Iovance Biotherapeutics (IOVA) and Audentes Therapeutics (BOLD).
What other stocks do shareholders of Novavax own?
Who are Novavax's key executives?
Novavax's management team includes the folowing people:
- Mr. Stanley Charles Erck, Pres, CEO & Director (Age 71)
- Mr. John Joseph Trizzino, Sr. VP, Chief Bus. Officer, CFO & Treasurer (Age 59)
- Mr. John A. Herrmann III, Sr. VP, Gen. Counsel & Corp. Sec. (Age 53)
- Dr. Gregory M. Glenn, Pres of R&D (Age 65)
- Mr. Sven Andréasson M.B.A., Sr. VP of Corp. Devel. (Age 67)
Who are Novavax's major shareholders?
Novavax's stock is owned by a variety of of institutional and retail investors. Top institutional investors include Northern Trust Corp (1.19%), Two Sigma Investments LP (0.86%), Millennium Management LLC (0.77%), Two Sigma Advisers LP (0.44%), Caption Management LLC (0.15%) and Rhumbline Advisers (0.14%). Company insiders that own Novavax stock include Barclay A Phillips, Gregory M Glenn, James F Young, John Trizzino, Michael A Mcmanus Jr and Stanley C Erck. View Institutional Ownership Trends for Novavax.
Which major investors are selling Novavax stock?
NVAX stock was sold by a variety of institutional investors in the last quarter, including GSA Capital Partners LLP, Chicago Equity Partners LLC, Virtus ETF Advisers LLC, MetLife Investment Advisors LLC, Paloma Partners Management Co, Creative Planning, California Public Employees Retirement System and D.A. Davidson & CO.. View Insider Buying and Selling for Novavax.
Which major investors are buying Novavax stock?
NVAX stock was bought by a variety of institutional investors in the last quarter, including Two Sigma Investments LP, Millennium Management LLC, Caption Management LLC, Two Sigma Advisers LP, Sargent Investment Group LLC, TD Asset Management Inc., Rhumbline Advisers and Jane Street Group LLC. Company insiders that have bought Novavax stock in the last two years include Barclay A Phillips, Gregory M Glenn, John Trizzino, Michael A Mcmanus Jr and Stanley C Erck. View Insider Buying and Selling for Novavax.
How do I buy shares of Novavax?
Shares of NVAX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Novavax's stock price today?
One share of NVAX stock can currently be purchased for approximately $1.92.
How big of a company is Novavax?
Novavax has a market capitalization of $735.07 million and generates $31.18 million in revenue each year. The biopharmaceutical company earns $-183,760,000.00 in net income (profit) each year or ($0.63) on an earnings per share basis. Novavax employs 347 workers across the globe.
What is Novavax's official website?
How can I contact Novavax?
Novavax's mailing address is 20 FIRSTFIELD ROAD, GAITHERSBURG MD, 20878. The biopharmaceutical company can be reached via phone at 240-268-2000 or via email at [email protected]
MarketBeat Community Rating for Novavax (NASDAQ NVAX)
MarketBeat's community ratings are surveys of what our community members think about Novavax and other stocks. Vote "Outperform" if you believe NVAX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe NVAX will underperform the S&P 500 over the long term. You may vote once every thirty days.
